Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Clouseau who wrote (998)	2/7/2000 4:38:00 PM
From: Bret Masterson	Read Replies (1) \| Respond to of 1029

Dave, (1) I had also sold my position in this stock (stop loss order at $40), but recently have been buying back in. With so many over valued stocks, ICN seems pretty reasonable in the mid 20s with the Rebetron royalty streams coming on, and potential for EE to turn-around. (2) All in all, I've never really trusted the management of the company too much, and am somewhat skeptical at their ability to prudently manage increasing levels of R&D. Would prefer to see the company bought out. Still, seems like the downside is pretty limited with some positive factors that could increase the value if they happen: a) Takeover bid b) EE turn-around c) Receiving compensation/return of factory in Yugo d) Generally increasing earnings trend (3) P.S. It was my birthday today, so I bought a few March 30 calls on this stock (purely speculative, but I felt lucky!!)